GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (OTCPK:SHPMF) » Definitions » Financial Strength

SHPMF (Shanghai Pharmaceuticals Holding Co) Financial Strength : 7 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co Financial Strength?

Shanghai Pharmaceuticals Holding Co has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Shanghai Pharmaceuticals Holding Co's Interest Coverage for the quarter that ended in Mar. 2025 was 5.71. Shanghai Pharmaceuticals Holding Co's debt to revenue ratio for the quarter that ended in Mar. 2025 was 0.19. As of today, Shanghai Pharmaceuticals Holding Co's Altman Z-Score is 2.09.


Competitive Comparison of Shanghai Pharmaceuticals Holding Co's Financial Strength

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co's Financial Strength Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Financial Strength falls into.


;
;

Shanghai Pharmaceuticals Holding Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Shanghai Pharmaceuticals Holding Co's Interest Expense for the months ended in Mar. 2025 was $-61 Mil. Its Operating Income for the months ended in Mar. 2025 was $350 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1,115 Mil.

Shanghai Pharmaceuticals Holding Co's Interest Coverage for the quarter that ended in Mar. 2025 is

Interest Coverage=-1*Operating Income (Q: Mar. 2025 )/Interest Expense (Q: Mar. 2025 )
=-1*349.595/-61.258
=5.71

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Shanghai Pharmaceuticals Holding Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6224.937 + 1114.927) / 39045.16
=0.19

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Shanghai Pharmaceuticals Holding Co has a Z-score of 2.09, indicating it is in Grey Zones. This implies that Shanghai Pharmaceuticals Holding Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.09 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Shanghai Pharmaceuticals Holding Co has the Financial Strength Rank of 7.


Shanghai Pharmaceuticals Holding Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pharmaceuticals Holding Co Business Description

Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2024, medical distribution is the largest segment, accounting for 91.3% of total revenue. It also has coverage of 31 provinces and cities nationwide.